Surgery Medical News about pruritic micropapular eruption

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Drug-induced pruritic micropapular eruption: anastrozole, a commonly used aromatase inhibitor
Dermatology Online Journal, 07/30/09

Bremec T et al. – Anastrozole, a selective nonsteroidal aromatase inhibitor is widely used as an adjuvant therapy for postmenopausal women with early hormone–sensitive breast cancer. There are few reports on cutaneous side effects of anastrozole. It may induce subacute cutaneous lupus erythematosus, erythema nodosum, cutaneous vasculitis, and nondescript skin eruptions. A 68–year–old woman was prescribed anastrozole after surgical removal of her breast cancer and adjuvant radiation therapy. Two months later she experienced a generalized pruritic micropapular eruption.

<< Previous
Pediatric melanoma: a single-institution experience of 150...

Next >>
Development and validation of mental practice as a training...

Mucocutaneous manifestations in 150 HIV-infected Indian patients and their relationship with CD4 lymphocyte counts
International Journal of STD & AIDS, 10/30/09 Relevance Score: 64%

Enlarging purple pruritic nodules on the dorsal neck
The Clinical Advisor, 11/05/09 Relevance Score: 63%

A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin
Canadian Journal of Gastroenterology, 10/12/09 Relevance Score: 43%

Eruptive disseminated Spitz naevi: dermatoscopic features
Clinical and Experimental Dermatology, 10/06/09 Relevance Score: 43%

Repeated episodes of fixed eruption 3 months after discontinuing pegylated interferon-alpha-2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection
Clinical and Experimental Dermatology, 10/16/09 Relevance Score: 42%